Literature DB >> 11713213

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

M Heffernan1, R J Summers, A Thorburn, E Ogru, R Gianello, W J Jiang, F M Ng.   

Abstract

Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with the beta-adrenergic pathway, particularly with the beta(3)-adrenergic receptors (beta(3)-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression of beta(3)-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice. The importance of beta(3)-AR was verified when long-term treatment with hGH and AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in the beta(3)-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR although both compounds increase beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713213     DOI: 10.1210/endo.142.12.8522

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Pharmacotherapy for obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; John J McNeil
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Authors:  Mahmoud M Habibullah; Syam Mohan; Nabeel Kashan Syed; Hafiz A Makeen; Qazi Mohammad Sajid Jamal; Hani Alothaid; Farkad Bantun; Alaa Alhazmi; Ali Hakamy; Yahia A Kaabi; Ghalia Samlan; Mohtashim Lohani; Neelaveni Thangavel; Mohamed Ahmed Al-Kasim
Journal:  Drug Des Devel Ther       Date:  2022-06-27       Impact factor: 4.319

3.  Growth hormone-releasing hormone (GHRH) polymorphisms associated with carcass traits of meat in Korean cattle.

Authors:  Hyun Sub Cheong; Du-Hak Yoon; Lyoung Hyo Kim; Byung Lae Park; Yoo Hyun Choi; Eui Ryong Chung; Yong Min Cho; Eng Woo Park; Il-Cheong Cheong; Sung-Jong Oh; Sung-Gon Yi; Taesung Park; Hyoung Doo Shin
Journal:  BMC Genet       Date:  2006-06-03       Impact factor: 2.797

Review 4.  Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.

Authors:  Mª Luisa Isidro; Fernando Cordido
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-12

Review 5.  Insulin-like growth factor-1 deficiency and metabolic syndrome.

Authors:  G A Aguirre; J Rodríguez De Ita; R G de la Garza; I Castilla-Cortazar
Journal:  J Transl Med       Date:  2016-01-06       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.